Table 1 Baseline patient characteristics according to the development of haemorrhagic transformation and symptomatic intracranial haemorrhage
Non-HT (n = 178) | HT (n = 23) | p value | Non-sICH (n = 187) | sICH (n = 14) | p value | |
|---|---|---|---|---|---|---|
Age, years | 76.0 (69.0–83.0) | 82.0 (75.0–87.0) | 0.020 | 77.0 (70.0–83.0) | 83.0 (75.0–87.3) | 0.033 |
Sex, female | 107 (60.1) | 13 (56.5) | 0.741 | 111 (59.4) | 9 (64.3) | 0.717 |
Time to the start of IVT, min | 150.0 (118.0–190.0) | 132.0 (110.0–163.0) | 0.204 | 150.0 (118.0–190.0) | 122.5 (108.8–160.8) | 0.134 |
Baseline NIHSS | 9.0 (6.0–14.0) | 14.0 (8.0–18.0) | 0.014 | 9.0 (6.0–14.0) | 16.0 (10.3–19.0) | 0.021 |
SBP, mmHg | 161.0 (143.0–185.0) | 172.0 (156.0–190.0) | 0.162 | 163.0 (143.0–186.0) | 167.5 (153.8–188.5) | 0.478 |
DBP, mmHg | 90.0 (81.0–100.0) | 100.0 (80.0–117.0) | 0.193 | 92.0 (81.0–100.0) | 90.0 (80.0–110.5) | 0.849 |
INR | 1.01 (0.95–1.07) | 1.10 (1.01–1.19) | 0.003 | 1.01 (0.95–1.08) | 1.09 (1.02–1.29) | 0.073 |
GFR, ml/min/1.73m2 | 63.51 (50.86–76.19) | 56.85 (44.0–63.91) | 0.040 | 62.53 (49.25–74.80) | 58.00 (43.47–64.85) | 0.256 |
Blood glucose, mmol/l | 6.65 (5.91–7.71) | 6.57 (6.02–8.68) | 0.736 | 6.64 (5.91–7.70) | 6.56(6.14–8.94) | 0.610 |
Haemoglobin, g/l | 134.0 (125.0–143.0) | 136.0 (128.0–149.0) | 0.399 | 134.0 (125.0–144.0) | 130.5 (124.5–140.5) | 0.440 |
Neutrophils, × 109/l | 4.56 (3.63–6.04) | 3.97 (3.46–5.53) | 0.420 | 4.57 (3.58–6.06) | 3.95 (3.26–4.55) | 0.117 |
Lymphocytes, × 109/l | 1.99 (1.46–2.57) | 1.73 (1.39–2.73) | 0.585 | 1.98 (1.44–2.57) | 1.76 (1.39–2.59) | 0.627 |
Monocytes, × 109/l | 0.64 (0.50–0.80) | 0.66 (0.52–0.88) | 0.480 | 0.64 (0.50–0.81) | 0.69 (0.49–0.92) | 0.614 |
NLR | 2.14 (1.57–3.39) | 2.27 (1.63–3.50) | 0.888 | 2.19 (1.57–3.44) | 2.07 (1.63–2.42) | 0.526 |
LMR | 3.01 (2.32–4.57) | 2.83 (2.22–3.33) | 0.273 | 3.00 (2.29–4.56) | 2.84 (2.39–3.21) | 0.425 |
Eosinophils, × 109/l | 0.13 (0.07–0.20) | 0.08 (0.05–0.12) | 0.026 | 0.12 (0.07–0.20) | 0.09 (0.06–0.21) | 0.454 |
Platelets, × 109/l | 217.5 (180.8–252.3) | 190.0 (163.0–243.0) | 0.097 | 216.0 (181.0–252.0) | 186.0 (150.8–244.8) | 0.086 |
Diabetes mellitus | 32 (18.0) | 3 (13.0) | 0.772 | 32 (17.1) | 3 (21.4) | 0.715 |
Atrial fibrillation at admission | 59 (33.1) | 16 (69.6) | 0.001 | 66 (35.3) | 9 (64.3) | 0.031 |
Previous stroke | 21 (19.0) | 3 (13.0) | 0.742 | 22 (11.8) | 2 (14.3) | 0.676 |
Pre-admission anticoagulant use | 14 (7.9) | 5 (21.7) | 0.049 | 16 (8.6) | 3 (21.4) | 0.133 |
Pre-admission antiaggregant use | 33 (18.5) | 3 (13.0) | 0.773 | 35 (18.7) | 1 (7.1) | 0.472 |